Oncotarget: Inflammatory microenvironment & hepatic macrophage in hepatocellular carcinoma
(Impact Journals LLC) " The incidence of hepatocellular carcinoma (HCC) is increasing worldwide, and HCC is amongst the leading causes of cancer death globally. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2021 Category: International Medicine & Public Health Source Type: news
Transarterial embolisation not cost effective vs sorafenib for hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news
Indigenous Americans: Global DNA pattern and gene expression signature in liver cancer
(Impact Journals LLC) Hepatocellular carcinoma (HCC), the main form of primary liver cancer, is one of the leading causes of tumor-related death worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news
HCV Cure Before HCC Diagnosis Associated With Improved Survival HCV Cure Before HCC Diagnosis Associated With Improved Survival
Do patients with HCV-related hepatocellular carcinoma who have achieved HCV cure before HCC diagnosis have improved survival compared with patients who are viraemic at HCC diagnosis?Journal of Viral Hepatitis (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 25, 2021 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news
Bariatric Surgery Reduces the Incidence of HCC Bariatric Surgery Reduces the Incidence of HCC
This study assessed the impact of bariatric surgery on the incidence of hepatocellular carcinoma in obese patients.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Landmark study launched to detect liver cancer early in Singapore
(Duke-NUS Medical School) - Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2021 Category: Cancer & Oncology Source Type: news
Landscape study launched to detect liver cancer early in Singapore
(Duke-NUS Medical School) - Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 3, 2021 Category: International Medicine & Public Health Source Type: news
Landmark study launched to detect liver cancer early in Singapore
(SingHealth) Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.The study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.The study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2021 Category: Cancer & Oncology Source Type: news
Cost-effectiveness evidence of hepatocellular carcinoma screening reviewed
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news
US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news
Antibiotics May Prolong PFS in HCC Patients on Immunotherapy Antibiotics May Prolong PFS in HCC Patients on Immunotherapy
Taking antibiotics 30 days before or after starting an immune checkpoint inhibitor was associated with a benefit in progression-free survival (PFS) for patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Detecting Antibodies to p16 Protein-Derived Peptides in HCC Detecting Antibodies to p16 Protein-Derived Peptides in HCC
This study suggests that circulating IgG antibodies to p16 protein might be a useful biomarker for hepatocellular carcinoma prognosis assessment as well as early HCC diagnosis.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC
Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Monofocal Hepatocellular Carcinoma: How Much Does Size Matter? Monofocal Hepatocellular Carcinoma: How Much Does Size Matter?
This study evaluated the appropriate staging of large monofocal hepatocellular carcinomas. How should tumor size impact treatment?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
